RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN OBESITY TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE 3 CLINICAL TRIALS
INTERNATIONAL BLEST SCIENTIFIC · 01.02.2026 · 2 (05)
DOI: 10.65671/7z5zjv05 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift INTERNATIONAL BLEST SCIENTIFIC, online erschienen am 01.02.2026. Verfasst von Luiz Felippe Mendes Caquetti.
Abstract (Originalsprache)
Introduction
Obesity represents one of the most prevalent chronic non-communicable diseases worldwide and is strongly associated with an increased risk of cardiometabolic disorders. In recent years, pharmacological therapies targeting the incretin system have significantly advanced obesity treatment. In this context, next-generation incretin-based drugs such as tirzepatide, a dual GLP-1/GIP receptor agonist, and retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, have demonstrated promising results in advanced clinical trials.
Objective
To compare the metabolic efficacy and safety profile of retatrutide-based triple agonism with tirzepatide-based dual agonism in the treatment of obesity using evidence from phase 3 randomized clinical trials.
Methods
A systematic review with comparative analysis was conducted using data from randomized clinical trials included in the SURMOUNT and TRIUMPH study programs. The analysis focused on outcomes including percentage body weight reduction, proportion of individuals achieving ≥30% weight loss, incidence of gastrointestinal adverse events, and treatment discontinuation rates.
Results
Findings indicated that tirzepatide produced an average body weight reduction of approximately 22%, whereas retatrutide achieved mean reductions close to 28.7%. A higher proportion of super-responders was also observed with retatrutide, with approximately 39.4% of participants achieving ≥30% weight reduction compared to approximately 10–15% observed with tirzepatide. Regarding safety outcomes, both medications showed predominantly gastrointestinal adverse events, although higher treatment discontinuation rates were associated with triple agonism.
Conclusion
Retatrutide-based triple agonism demonstrates superior weight loss magnitude and a higher proportion of super-responders compared with tirzepatide-based dual agonism. However, this greater metabolic efficacy appears to be associated with slightly reduced tolerability, highlighting the importance of individualized clinical decision-making in obesity pharmacotherapy.
Zitieren
APA
Caquetti, L. F. M. (2026). RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN OBESITY TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE 3 CLINICAL TRIALS. INTERNATIONAL BLEST SCIENTIFIC, 2(05). https://doi.org/10.65671/7z5zjv05
Vancouver
Caquetti LFM. RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN OBESITY TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE 3 CLINICAL TRIALS. INTERNATIONAL BLEST SCIENTIFIC. 2026;2(05). doi:10.65671/7z5zjv05
BibTeX
@article{Caquetti2026,
author = {Caquetti, Luiz Felippe Mendes},
title = {RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN OBESITY TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE 3 CLINICAL TRIALS},
journal = {INTERNATIONAL BLEST SCIENTIFIC},
year = {2026},
volume = {2},
number = {05},
doi = {10.65671/7z5zjv05}
}
EUVIMED